Pular para o conteúdo principal

Eu Sou Você Amanhã? Como as lições aprendidas com a crise dos opioides e a epidemia de tabagismo podem ser úteis na regulação do uso da Cannabis medicinal

Revista Fitos
A regulação de medicamentos torna-se especialmente desafiadora quando envolve substâncias com potencial terapêutico e de abuso, caso da Cannabis medicinal. Este artigo reflete sobre as lições das crises dos opioides e do tabaco para a regulamentação da Cannabis medicinal. Ambas as epidemias expõem falhas regulatórias e estratégias empresariais que contribuíram para graves danos à saúde pública. Com base nessas experiências, são propostas recomendações concretas, que vão desde marcos regulatórios internacionais harmonizados até medidas rígidas de controle de marketing e conflitos de interesse, visando aproveitar os benefícios terapêuticos da Cannabis sem repetir erros do passado. Assim, busca-se assegurar que a introdução da Cannabis medicinal ocorra de forma segura, eficaz e protegida contra desvio de uso ou influência indevida de interesses comerciais.
DOI
10.32712/2446-4775.2025.1820
Identificação
Referências do artigo
1. Legare CA, Raup-Konsavage WM, Vrana KE. Therapeutic Potential of Cannabis, Cannabidiol, and Cannabinoid-Based Pharmaceuticals. Pharmacology. 2022; 107(3-4): 131-49. [https://doi.org/10.1159/000521683]. 2. CDC. Understanding the Opioid Overdose Epidemic [Internet]. Overdose Prevention. 2024 [cited 2025 Jan 4]. Available from: [https://www.cdc.gov/overdose-prevention/about/understanding-the-opioid- overdose-epidemic.html]. 3. Hébert AH, Hill AL. Impact of opioid overdoses on US life expectancy and years of life lost, by demographic group and stimulant co-involvement: a mortality data analysis from 2019 to 2022. Lancet Reg Health – Am [Internet]. 2024 Aug 1; 36. [cited 2025 Jan 4] Available from: [https://www.thelancet.com/pdfs/journals/lanam/PIIS2667-193X(24)00140-6.pdf]. 4. Bowra A, Perez-Brumer A, Forman L, Kohler JC. Interconnected influence: Unraveling purdue pharmaceutical’s role in the global response to the opioid crisis. Int J Drug Policy [Internet]. 2024 Nov 1; 133: 104604. [cited 2025 Jan 4]. Available from: [https://www.sciencedirect.com/science/article/pii/S0955395924002883]. 5. Kolodny A. How FDA Failures Contributed to the Opioid Crisis. AMA J Ethics [Internet]. 2020 Aug 1; 22(8): 743–50. [cited 2025 Jan 4]. Available from: [https://journalofethics.ama-assn.org/article/how-fda-failures-contributed-opioid- crisis/2020-08]. 6. Americas TLRH. Opioid crisis: addiction, overprescription, and insufficient primary prevention. Lancet Reg Health – Am [Internet]. 2023 Jul 1; 23. [cited 2025 Jan 4]. Available from: [https://www.thelancet.com/journals/lanam/article/PIIS2667-193X(23)00131-X/fulltext]. 7. Chiu C, Wong A, Chhen J, Roderos AJAJ, Apollonio DE. Retail chain pharmacy opioid dispensing practices from 1997 to 2020: A content analysis of internal industry documents. Drug Alcohol Depend Rep. 2023 Dec; 9: 100199. 8. Van Zee A. The Promotion and Marketing of OxyContin: Commercial Triumph, Public Health Tragedy. Am J Public Health [Internet]. 2009 Feb; 99(2): 221–7. [cited 2025 Jun 30] Available from: [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2622774/]. 9. Clark K, Rogers H. Corrupting Influence: Purdue and the WHO [Internet]. 2019 May; [cited 2025 Jan 6] p. 43. Available from: [https://katherineclark.house.gov/_cache/files/a/a/aaa7536a-6db3-4192-b943- 364e7c599d10/818172D42793504DD9DFE64B77A77C0E.5.22.19-who-purdue-report-final.pdf]. 10. Global Burden of Disease: GBD cause and risk summaries (Tobacco) [Internet]. 2019 [cited 2024 May 3]. Available from: [https://www.thelancet.com/gbd/summaries]. 11. Centers for Disease Control and Prevention. The Health Consequences of Smoking: A Report of the Surgeon General [Internet]. Washington, D.C: Dept. of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health. 2004; [cited 2019 Apr 2]. Report No.: ISBN 0-16- 051576-2. Available from: [http://www.cdc.gov/tobacco/data_statistics/sgr/2004/]. 12. Committee on Environmental Health, Committee on Substance Abuse, Committee on Adolescence, Committee on Native American Child Health. Tobacco Use: A Pediatric Disease. Pediatrics [Internet]. 2009 Nov 1; 124(5): 1474–87. [cited 2017 Jul 8]. Available from: [http://pediatrics.aappublications.org/content/124/5/1474]. 13. WPRO | Smoking Statistics [Internet]. WPRO. 2016 [cited 2016 May 16]. Available from: [http://www.wpro.who.int/mediacentre/factsheets/fs_20020528/en/]. 14. Palacios A, Pinto M, Barros L, Bardach A, Casarini A, Rodríguez Cairoli F, et al. A importância de aumentar os impostos do tabaco no Brasil. [Internet]. Instituto de Efetividade Clínica e Sanitária. 2020 Dec; [cited 2021 May 10]. Available from: [https://www.iecs.org.ar/wp-content/uploads/tabaco-brasil.pdf]. 15. Pinto M, Bardach A, Costa MG, Simões e Senna KM, Barros LB, Moraes AC, et al. Carga da doença e econômica atribuível ao tabagismo no Brasil e potencial impacto do aumento de preços por meio de impostos [Internet]. Buenos Aires: s. Instituto de Efectividad Clínica y Sanitaria; Maio de 2024. [cited 2024 Jun 17]. Available from: [https://tabaco.iecs.org.ar/wp- content/uploads/2024/05/20TABAQUISMO-BRASIL.pdf]. 16. Flintstones brought to You by Winston Cigarettes [Internet]. 2014. [cited 2025 Jan 5]. Available from: [https://www.youtube.com/watch?v=LW0m5Gym4ys]. 17. Heidt C, Dal MS, Graen L, Ouédraogo N, Schaller K. Tobacco and e-cigarette promotion on social media: the case of German rap music. Tob Control. 2024 Jul 11; tc-2024-058683. Online ahead of print. [https://doi.org/10.1136/tc-2024-058683]. 18. Ling PM, Glantz SA. Historical and political context for Philip Morris International’s continuing medical education courses on harm reduction. Tob Control [Internet]. 2025 Jan 3; [cited 2025 Jan 5]. Available from: [https://doi.org/10.1136/tc-2024-059015]. 19. Lewan T. Dark secrets of tobacco company exposed. Tob Control [Internet]. 1998 Sep 1; 7(3): 315–9. [cited 2025 Jan 5]. Available from: [https://doi.org/10.1136/tc.7.3.315]. 20. Rigotti NA, Tindle HA. The fallacy of “light” cigarettes. BMJ. 2004 Mar 13; 328(7440): E278-279. 21. European Commission - Directorate General for Health and Food Safety. Opinion on additives used in tobacco products (Opinion 2): tobacco additives II. [Internet]. Luxembourg: Publications Office; 2016 [cited 2021 Jun 18]. 107 p. Available from: [https://data.europa.eu/doi/10.2875/723392]. 22. Silva ALO, Moreira JC. Sais de nicotina e nicotina sintética: novos desafios para um velho problema. Rev Bras Cancerol [Internet]. 2022 Nov 9; 68(4): e-202846. [cited 2023 Jul 3]. Available from: [https://doi.org/10.32635/2176-9745.RBC.2022v68n4.2846]. 23. Apollonio DE, Bero LA. The Creation of Industry Front Groups: The Tobacco Industry and “Get Government Off Our Back.” Am J Public Health [Internet]. 2007 Mar; 97(3): 419–27. [cited 2025 Jan 5]. Available from: [https://doi.org/10.2105/AJPH.2005.081117]. 24. Bero LA. Tobacco industry manipulation of research. Public Health Rep [Internet]. 2005; 120(2): 200-8. [cited 2019 Apr 16]. Available from: [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1497700/]. 25. Mamudu HM, Hammond R, Glantz SA. Project Cerberus: Tobacco Industry Strategy to Create an Alternative to the Framework Convention on Tobacco Control. Am J Public Health [Internet]. 2008 Sep; 98(9): 1630-42. [cited 2016 Jul 13]. Available from: [https://doi.org/10.2105/AJPH.2007.129478]. 26. Mathias M. Philip Morris tenta adiar decisão sobre cigarro eletrônico. “Anvisa está madura para debater o assunto”, diz sociedade civil [Internet]. O Joio e O Trigo. 2022 [cited 2023 Feb 17]. Available from: [https://ojoioeotrigo.com.br/2022/06/philip-morris-tenta-adiar-decisao-sobre-cigarro-eletronico-anvisa-esta-madura-para-debater-o-assunto-diz-sociedade- civil/]. 27. Landman A, Glantz SA. Tobacco Industry Efforts to Undermine Policy-Relevant Research. Am J Public Health [Internet]. 2009 Jan; 99(1): 45–58. [cited 2016 May 23] Available from: [https://doi.org/10.2105/AJPH.2007.130740]. 28. WHO. Tobacco Free Initiative & Advancing knowledge on regulating tobacco products (‎2000: Oslo, Norway)‎. Advancing knowledge on regulating tobacco products: monograph. World Health Organization. IRIS-Institutional Repository for Information Sharing. 2001. 120p. [cited 2025 Jul 2]. Available from: [https://iris.who.int/handle/10665/66741]. 29. Dewhirst T. ‘Beyond nicotine’ marketing strategies: Big Tobacco diversification into the vaping and Cannabis product sectors. Tob Control [Internet]. 2023 May 1; 32(3): 402–4. [cited 2025 Jan 5]. Available from: [https://doi.org/10.1136/tobaccocontrol-2021-056798].
Publicado por (Instituto)